cryptocurrencies banks, Top

Analyst: The interest rate of the European Central Bank will be pushed to the low end of the neutral range. Marchel Alexandrovich, an economist at Saltmarsh Economics, said that the European Central Bank cut interest rates by 25 basis points again, which is the fourth time in this easing cycle. The monetary policy statement reiterated that the Committee would not commit to a specific interest rate path in advance. However, the new forecast shows that the core inflation rate is 1.9% in 2026 and 2027, which indicates that interest rates may continue to push to the low end of the neutral range.European Central Bank: It is estimated that the GDP growth rate will be 0.7% in 2024, 1.1% in 2025, 1.4% in 2026 and 1.3% in 2027. (It is expected to be 0.8%, 1.3% and 1.5% respectively in September) It is estimated that the core inflation rate will be 2.9% in 2024, 2.3% in 2025 and 1.9% in 2026. (It is expected to be 2.8%, 2.3% and 2.0% respectively in September) It is estimated that the core inflation rate will be 1.9% in 2027.China Chengtong and China Yizhong set up an enterprise management center with a capital contribution of 6.25 billion yuan. According to Tianyancha App, Zhongcheng (Beijing) Enterprise Management Center (Limited Partnership) was recently established. The executive partner is Yizhong Group Sunac Technology Development Co., Ltd., with a capital contribution of 6.25 billion yuan. The business scope is enterprise management and enterprise management consulting. It is owned by China Chengtong's Beijing Chengtong Capital Investment Co., Ltd., China Yizhong Group Co., Ltd. and its subsidiary Sunac Technology Development Co., Ltd.

The latest collection price of the heavy anticancer star drug Regofibril has dropped to a minimum of more than 4 yuan per tablet. The reporter learned at the scene of the tenth batch of drug collection that the anti-tumor drug Regofibril tablets with annual sales of more than 1 billion yuan have been auctioned by this collection, and the price has almost dropped to between 4 yuan and 6 yuan, which is 90% lower than the price limit. Nanjing Zhengda Tianqing is expected to win the bid in the first round of quotation. Regofibril can treat colorectal cancer, liver cancer and other cancers. Its original research manufacturer is Bayer, which occupies almost all the market share in China. The price of this collection is about 172 yuan per tablet. (science and technology innovation board Daily)The United States ITC issued a 337-part final ruling on the wireless front-end module and its downstream equipment. According to the China Trade Relief Information Network, on December 10, 2024, the United States International Trade Commission (ITC) issued a notice saying that it made a 337-part final ruling on a specific wireless front-end module and its downstream equipment: the preliminary ruling (No.13) made by the administrative judge in this case on November 8, 2024 will not be reviewed, that is, based on the withdrawal of the applicant, Kangxi Communication Technology (Shanghai) Co., Ltd. and Ruijie Network Co., Ltd. are listed as defendants.During the "slimming" of the brokerage business department, more than 100 companies were cancelled during the year, and the competition turned to differentiated services. The brokerage business of brokerage companies is welcoming a new round of changes. In the past few days, a number of brokers have announced the cancellation of their relevant business departments. According to the reporter's incomplete statistics, in the past two weeks, many brokers such as Nanjing Securities, Guosen Securities and Pacific Securities announced that they would "streamline" their business departments. Looking at it for a long time, more than 35 brokers have issued announcements during the year, "downsizing" hundreds of business departments. Insiders pointed out that the traditional offline outlet business development model has increasingly shown drawbacks and high cost pressure; At the same time, more and more customers rely on online transactions and mobile terminal transactions, so it is imperative to "streamline" the business department to reduce costs and increase efficiency. Future competition depends more on differentiated financial management and trading services. (Shell Finance)

China Chengtong and China Yizhong set up an enterprise management center with a capital contribution of 6.25 billion yuan. According to Tianyancha App, Zhongcheng (Beijing) Enterprise Management Center (Limited Partnership) was recently established. The executive partner is Yizhong Group Sunac Technology Development Co., Ltd., with a capital contribution of 6.25 billion yuan. The business scope is enterprise management and enterprise management consulting. It is owned by China Chengtong's Beijing Chengtong Capital Investment Co., Ltd., China Yizhong Group Co., Ltd. and its subsidiary Sunac Technology Development Co., Ltd.Guan Qingyou: I am optimistic about the stock market by cutting interest rates and lowering the RRR. For example, Guan Qingyou, president and chief economist of the Financial Research Institute, said that lowering the RRR and raising interest rates will definitely happen, and from the downward trend of previous interest rates, it should be faster. Regarding the current market conditions, Guan Qingyou said that different subjects have different judgments on the market trend in one or two trading days, but he is still optimistic, and said that the positive impact of the current policy change on the capital market cannot be underestimated. Combining industrial structure and policy orientation, Guan Qingyou said that consumer companies, technology companies, and mergers and acquisitions involving the transformation and upgrading of traditional industries to emerging formats are all his optimistic directions. In addition, for the economic growth target in 2025, Guan Qingyou believes that "the target of 5% can still be contested". He also said that 2025 will be better than 2024. "In 2025, the adjustment of policies will bring more increments to the market and industry." (sohu finance)European Central Bank: It plans to stop reinvesting in the Emergency Anti-epidemic Bond Purchase Program (PEPP) by the end of 2024. Continue to reduce the emergency anti-epidemic bond purchase program (PEPP) by 7.5 billion euros per month.